Other Clinical Trial - Evaluation of Pharmacist Intervention for

Status Active, not recruiting

Clinical Trial Summary

Type 2 diabetes is a chronic disease that can lead to a number of complications if uncontrolled and there is a projected increase of 33% patients living with diabetes over the next 10 years. There can be improvements to modifiable risk factors such as diet and exercise, in addition to medications. Treatment often involves a multidisciplinary approach with a physician, endocrinologist, dietitian, pharmacist and other support health professionals as required. This study will evaluate the effects of the pharmacists (or pharmD interns) intervention, looking at changes to the patients HbA1C, which is a measure of the patients blood glucose control over the previous 3 months as well as the patients understanding and comfort with managing their own diabetes via participant survey.

Clinical Trial Description

Recruitment will begin in July 2022, potential participants can self-refer or another healthcare provider may discuss the study and provide contact information to the study team for all interested potential participants. These potential participants would then be screened for eligibility by the pharmacist or PharmD (Doctor of Pharmacy) Intern. The goal is to enroll 60 participants in the study. All participants must provide consent to participate and will be asked to complete a participant survey. All participants who consented will then be randomized into a control group which will not receive pharmacist intervention during the study period, or the intervention group which will receive pharmacist/PharmD Intern led intervention which includes a medication review, optimizing medication treatment options and frequent follow up and diabetes education. The control group participants will be offered pharmacist intervention following the study period. All participants will be asked to complete a participant survey at the start and end of the study. All participants will also have standard care from their physicians and other healthcare team members as required which would be standard of practice. All participants would also be asked to repeat their blood work at the end of the study period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05442840
Study type	Interventional
Source	University of Manitoba
Contact
Status	Active, not recruiting
Phase	N/A
Start date	July 4, 2022
Completion date	October 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting	`NCT04954313` - Baseline Oral Health Study: UnCoVer the Connections to General Health	Phase 4
Not yet recruiting	`NCT06437782` - Exploration of Health Literacy in Diabetes in Reunion Island and France
Completed	`NCT01354925` - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan	Phase 4
Completed	`NCT01206725` - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction	N/A
Completed	`NCT00997282` - A Study of OPC-262 in Patients With Type 2 Diabetes	Phase 2/Phase 3
Completed	`NCT00637546` - Gait and Balance of Diabetes Type 2 Patients	Phase 2/Phase 3
Completed	`NCT00464880` - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy	Phase 1/Phase 2
Withdrawn	`NCT02057497` - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms	N/A
Active, not recruiting	`NCT05014204` - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes	N/A
Recruiting	`NCT03662217` - Personalized Nutrition for Diabetes Type 2	N/A
Completed	`NCT04276051` - Cryovagotomy Diabetes Trial	N/A
Completed	`NCT02569684` - Effects of Prebiotics on GLP-1 in Type 2 Diabetes	N/A
Active, not recruiting	`NCT01933529` - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)	Phase 2
Terminated	`NCT01722474` - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.	N/A
Completed	`NCT00977262` - Postprandial Inflammation and Fatty Acids	N/A
Completed	`NCT00518427` - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine	Phase 4
Recruiting	`NCT05378620` - Project Dulce for Filipino-Americans With Type 2 Diabetes	N/A
Recruiting	`NCT03834207` - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy	N/A
Active, not recruiting	`NCT05228067` - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms